1
|
Di Cristofano A and Ellenson LH:
Endometrial carcinoma. Annu Rev Pathol. 2:57–85. 2007.
|
2
|
Macwhinnie N and Monaghan H: The use of
P53, PTEN, and CerbB-2 to differentiate uterine serous papillary
carcinoma from endometrioid endometrial carcinoma. Int J Gynecol
Cancer. 14:938–946. 2004. View Article : Google Scholar : PubMed/NCBI
|
3
|
Wu W, Slomovitz BM, Celestino J, Chung L,
Thornton A and Lu KH: Coordinate expression of Cdc25B and ER-alpha
is frequent in low-grade endometrioid endometrial carcinoma but
uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Cancer Res. 63:6195–6199. 2003.PubMed/NCBI
|
4
|
Matter K and Balda MS: Functional analysis
of tight junctions. Methods. 30:228–234. 2003. View Article : Google Scholar : PubMed/NCBI
|
5
|
Swisshelm K, Macek R and Kubbies M: Role
of claudins in tumorigenesis. Adv Drug Deliv Rev. 57:919–928. 2005.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Morin PJ: Claudin proteins in human
cancer: promising new targets for diagnosis and therapy. Cancer
Res. 65:9603–9606. 2005. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yoshida H, Sumi T, Zhi X, Yasui T, Honda K
and Ishiko O: Claudin-4: a potential therapeutic target in
chemotherapy-resistant ovarian cancer. Anticancer Res.
31:1271–1277. 2011.PubMed/NCBI
|
8
|
Hayes MP and Ellenson LH: Molecular
alterations in uterine serous carcinoma. Gynecol Oncol.
116:286–289. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Long H, Crean CD, Lee WH, Cummings OW and
Gabig TG: Expression of Clostridium perfringens enterotoxin
receptors claudin-3 and claudin-4 in prostate cancer epithelium.
Cancer Res. 61:7878–7881. 2001.
|
10
|
Zhu Y, Brännström M, Janson PO and
Sundfeldt K: Differences in expression patterns of the tight
junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface
epithelium as compared to epithelia in inclusion cysts and
epithelial ovarian tumours. Int J Cancer. 118:1884–1891. 2006.
View Article : Google Scholar
|
11
|
Nichols LS, Ashfaq R and Iacobuzio-Donahue
CA: Claudin 4 protein expression in primary and metastatic
pancreatic cancer: support for use as a therapeutic target. Am J
Clin Pathol. 121:226–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
12
|
Shang X, Lin X, Alvarez E, Manorek G and
Howell SB: Tight junction proteins claudin-3 and claudin-4 control
tumor growth and metastases. Neoplasia. 14:974–985. 2012.PubMed/NCBI
|
13
|
Santin AD, Bellone S, Marizzoni M, et al:
Overexpression of claudin-3 and claudin-4 receptors in uterine
serous papillary carcinoma: novel targets for a type-specific
therapy using Clostridium perfringens enterotoxin (CPE).
Cancer. 109:1312–1322. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Villena-Heinsen C, Friedrich M, Ertan AK,
Farnhammer C and Schmidt W: Human ovarian cancer xenografts in nude
mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine
and titanocene dichloride. Anticancer Drugs. 9:557–563. 1998.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Armstrong DK, Bundy B, Wenzel L, et al:
Gynecologic Oncology Group. Intraperitoneal cisplatin and
paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Liu Y, Chen L, He X, et al: Enhancement of
therapeutic effectiveness by combining liposomal honokiol with
cisplatin in ovarian carcinoma. Int J Gynecol Cancer. 18:652–659.
2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Rosanò L, Cianfrocca R, Spinella F, Di
Castro V, Natali PG and Bagnato A: Combination therapy of
zibotentan with cisplatinum and paclitaxel is an effective regimen
for epithelial ovarian cancer. Can J Physiol Pharmacol. 88:676–681.
2010.PubMed/NCBI
|
18
|
Kominsky SL, Vali M, Korz D, et al:
Clostridium perfringens enterotoxin elicits rapid and
specific cytolysis of breast carcinoma cells mediated through tight
junction proteins claudin 3 and 4. Am J Pathol. 164:1627–1633.
2004. View Article : Google Scholar
|
19
|
Litkouhi B, Kwong J, Lo CM, et al:
Claudin-4 overexpression in epithelial ovarian cancer is associated
with hypomethylation and is a potential target for modulation of
tight junction barrier function using a C-terminal fragment of
Clostridium perfringens enterotoxin. Neoplasia. 9:304–314.
2007. View Article : Google Scholar
|
20
|
Gao Z, Xu X, McClane B, et al: C terminus
of Clostridium perfringens enterotoxin downregulates CLDN4
and sensitizes ovarian cancer cells to Taxol and Carboplatin. Clin
Cancer Res. 17:1065–1074. 2011.
|